Musings from The Power List: Miguel Forte - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Musings from The Power List: Miguel Forte

Scientific progress alone isn't enough, says Miguel Forte, who argues that reimbursement and patient access will shape the next decade of cell and gene therapy

  • By

  • Miguel Forte

  • September 8, 2026

  • 5 min

Share

Clinical Scorecard: Musings from The Power List: Miguel Forte

At a Glance

CategoryDetail
ConditionCell and Gene Therapy
Key MechanismsManufacturing capacity, clinical delivery, reimbursement models
Target PopulationPatients with unmet medical needs
Care SettingClinical and regulatory environments

Key Highlights

  • Establishment of ISCT's clinical pillar with a Chief Medical Officer
  • Challenges in patient access due to manufacturing and reimbursement constraints
  • Progress in allogeneic cell therapies derived from iPSCs
  • Need for new business models to expand patient access
  • Importance of faster clinical trial approvals for evidence generation

Guideline-Based Recommendations

Diagnosis

    Management

    • Strengthen the value proposition and clinical data to attract investment
    • Consider operational changes for faster clinical trial approvals

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Patients with unmet medical needs in cell and gene therapy

        Potential for long-lasting, curative outcomes with new therapies

        Clinical Best Practices

        • Adopt pragmatic approaches in Health Technology Assessment decisions
        • Support flexible reimbursement models reflecting long-term therapy value

        Related Resources & Content

          Original Source(s)

          Musings from The Power List: Miguel Forte

          • by Miguel Forte

          • September 8, 2026

          Related Content

          Balanced Component and Whole-Blood Transfusion Practices in US Trauma Centers

          This Week’s CGT News: Bristol Myers Ends Cellares Manufacturing Agreement

          A first-in-human study reduces stem-cell collection and manufacturing times, Bristol Myers ends its Breyanzi agreement with Cellares, and two approaches strengthen CAR T-cell activity against solid tumors

          • August 31, 2026

          • 5 min
          Correction: Transplantation outcomes in Philadelphia-positive acute lymphoblastic leukemia with additional cytogenetic abnormalities: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation